Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

January 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Breast Neoplasms

Interventions

DRUG

PF-04691502

PF-04691502 administered orally at 8 mg as a continuous daily dosing schedule

DRUG

Exemestane

Exemestane administered orally at 25 mg as a continuous daily dosing schedule

DRUG

Exemestane

Exemestane administered orally at 25 mg as a continuous daily dosing schedule